Literature DB >> 9425898

Association of a human G-protein beta3 subunit variant with hypertension.

W Siffert1, D Rosskopf, G Siffert, S Busch, A Moritz, R Erbel, A M Sharma, E Ritz, H E Wichmann, K H Jakobs, B Horsthemke.   

Abstract

Hypertension is a common disorder of multifactorial origin that constitutes a major risk factor for cardiovascular events such as stroke and myocardial infarction. Previous studies demonstrated an enhanced signal transduction via pertussis toxin-sensitive G proteins in lymphoblasts and fibroblasts from selected patients with essential hypertension. We have detected a novel polymorphism (C825T) in exon 10 of the gene encoding the beta3 subunit of heterotrimeric G proteins (GNB3). The T allele is associated with the occurrence of a splice variant, GNB3-s (encoding G beta3-s), in which the nucleotides 498-620 of exon 9 are deleted. This in-frame deletion causes the loss of 41 amino acids and one WD repeat domain of the G beta subunit. By western-blot analysis, G beta3-s appears to be predominantly expressed in cells from individuals carrying the T allele. Significant enhancement of stimulated GTPgammaS binding to Sf9 insect cells expressing G beta3-s together with G alpha(i)2 and G gamma5 indicates that this splice variant is biologically active. Genotype analysis of 427 normotensive and 426 hypertensive subjects suggests a significant association of the T allele with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9425898     DOI: 10.1038/ng0198-45

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  141 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 2.  Use of gene markers to guide antihypertensive therapy.

Authors:  S T Turner; G L Schwartz; A B Chapman; E Boerwinkle
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 3.  Heredity and the autonomic nervous system in human hypertension.

Authors:  D T O'Connor; P A Insel; M G Ziegler; V Y Hook; D W Smith; B A Hamilton; P W Taylor; R J Parmer
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

Review 4.  Cardiac genes and gene databases for cardiovascular disease genetics.

Authors:  K T Tan; A Dempsey; C C Liew
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

5.  The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis.

Authors:  J R Ortlepp; R Hoffmann; F Ohme; J Lauscher; F Bleckmann; P Hanrath
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

Review 6.  Drug-gene interactions between genetic polymorphisms and antihypertensive therapy.

Authors:  Hedi Schelleman; Bruno H Ch Stricker; Anthonius De Boer; Abraham A Kroon; Monique W M Verschuren; Cornelia M Van Duijn; Bruce M Psaty; Olaf H Klungel
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  A new approach to SNP genotyping with fluorescently labeled mononucleotides.

Authors:  Kyoko Takatsu; Toyokazu Yokomaku; Shinya Kurata; Takahiro Kanagawa
Journal:  Nucleic Acids Res       Date:  2004-04-15       Impact factor: 16.971

8.  Association between the G-protein β3 subunit C825T polymorphism with essential hypertension: a meta-analysis in Han Chinese population.

Authors:  Jiapeng Lu; Qingqing Guo; Ling Zhang; Wei Wang
Journal:  Mol Biol Rep       Date:  2012-06-20       Impact factor: 2.316

9.  Homozygous 825T allele of the GNB3 protein influences the susceptibility of Japanese to dyspepsia.

Authors:  Tomomitsu Tahara; Tomiyasu Arisawa; Tomoyuki Shibata; Fangyu Wang; Masakatsu Nakamura; Mikijyu Sakata; Ichiro Hirata; Hiroshi Nakano
Journal:  Dig Dis Sci       Date:  2007-08-24       Impact factor: 3.199

Review 10.  Genetics of hypertension. Therapeutic implications.

Authors:  S O'Byrne; M Caulfield
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.